ClinicalTrials.gg
CompletedNCT00684190Updated Dec 3, 2010

Drug Interaction Study Between AZD3355 and Nexium

A Phase 1 interventional study of AZD3355 and Esomeprazole in Gastroesophageal Reflux Disease, sponsored by AstraZeneca. Completed at 1 site in Sweden. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-12-03.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing lesogaberan in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. lesogaberan · Gastroesophageal Reflux.

Enrollment
7th of 10
30 · median 51
Started
2008
with 3 others
Phase 1
4 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
9 of 10
AstraZeneca

Among the 10 studies testing lesogaberan in Gastroesophageal Reflux, this one is the 7th largest by enrollment, is one of 4 that started in 2008, is one of 4 in phase 1, and was the 2nd registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 10 studies testing lesogaberan in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →

About lesogaberan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing lesogaberan in Gastroesophageal Reflux as a file.
02

Study summary

The purpose of the study is to evaluate if AZD3355 and Nexium interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.

03

Conditions studied

  • Gastroesophageal Reflux Disease

Keywords

  • Reflux Inhibitor
  • GERD
  • PPI Interaction
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written
  • Females no
  • Clinically normal physical findings

Exclusion criteria

Exclusion Criteria:

  • illness within 2 weeks prior to the first dose of product
  • History of clinically significant disease
  • Use of prescribed medication during the 2 weeks before administration of the first dose of investigational product
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    1

    AZD3355 150 mg

    Drug: AZD3355

  • Experimental
    2

    Esomeprazole 40mg

    Drug: Esomeprazole

  • Experimental
    3

    AZD3355 150mg/Esomeprazole 40mg

    Drug: AZD3355 · Drug: Esomeprazole

Interventions

  • 150 mg bid, oral, 7 days

    Also known as: Lesogaberan

  • 40 mg od, oral, 7 days

    Also known as: Nexium

06

What researchers measure

Primary outcomes

  1. PK variables

    Time frame: Frequent sampling occasions during day 7 each treatment period

Secondary outcomes

  1. 4-BOH cholesterol

    Time frame: Sampling occasions during day 7 one treatment period (AZD3355 alone)

  2. Safety variables (adverse events, blood pressure, pulse, safety lab)

    Time frame: During the whole treatment period

07

Study locations

1 site
  • Research Site
    Uppsala, Sweden
08

References and documents

Publications

  • Niazi M, Silberg DG, Miller F, Ruth M, Holmberg AA. Evaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects. Drugs R D. 2010;10(4):243-51. doi: 10.2165/11588180-000000000-00000. PubMed 21171670 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2008
First posted
May 26, 2008
Start
Mar 2008
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Last update
Dec 3, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00684190
Lead sponsor
AstraZeneca
First posted
May 26, 2008
Start date
Mar 2008
Primary completion
Jun 2008
Completion
Jun 2008
Last update
Dec 3, 2010

Study contacts

Eva Ersdal, PhD
study director · AstraZeneca R&D, Mölndal, Sweden
Jan Vouis, MD
principal investigator · Quintiles AB, Uppsala, Sweden

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lesogaberan · Esomeprazole

Start the discussion